Kiniksa Pharmaceuticals, Ltd. (KNSA) has a consensus analyst rating of Buy, based on 10 analysts covering the stock. Of those, 10 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for KNSA is $55.67, representing a +18.6% upside from the current price of $46.92. Price targets range from a low of $50.00 to a high of $62.00.
